Anti-CD19/CD20 chimeric antigen receptor T cell therapy - Shanghai Longyao Biotechnology

Drug Profile

Anti-CD19/CD20 chimeric antigen receptor T cell therapy - Shanghai Longyao Biotechnology

Alternative Names: Mixed CD19/CD20 CAR-T cells therapy - Shanghai Longyao Biotechnology

Latest Information Update: 05 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai Longyao Biotechnology
  • Developer Shanghai Jiao Tong University; Shanghai Longyao Biotechnology; Xuzhou Medical University
  • Class CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II B cell lymphoma

Most Recent Events

  • 01 Mar 2017 Phase-I/II clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (NCT03207178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top